Did you know that in a lean drug discovery model more resources are invested in the early stages of drug discovery? This allows for better prediction, testing and learning cycles, and serves to feed the later, long and expensive development stages with candidate molecules with a higher chance of success.

Pharmacelera offers unique and customised drug discovery services to small biotech companies, large pharmaceutical R&D departments, public research institutions and full-service clinical research organisations (CRO).

Its methodology exploits an untapped chemical space, finds starting points with greater chemical diversity and enables the development of new therapies for unmet medical needs and the search for new treatments. In turn, it assists companies in the drug discovery stages of target identification, lead identification, hit-to-lead and lead optimisation by searching for novel hits, improving ligand binding properties.

We interviewed (in catalan) Enric Herrero, CTO and co-founder of Pharmacelera.